---
title: "Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Guidelines questions"
description: "Guidelines questions on Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does NCCN recommend TRODELVY for metastatic TNBC? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/guidelines"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer: Guidelines questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Trodelvy](https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf)

## Guidelines

<a id="trodelvy-nccn"></a>

### Does NCCN recommend TRODELVY for metastatic TNBC?

> “National Comprehensive Cancer Network® (NCCN®): Sacituzumab govitecan-hziy<sup>a</sup> (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC with PD-L1 CPS <10<sup>b</sup> or who are not candidates for PD-1/PD-L1 inhibitor therapy and with no germline BRCA1/2 PV<sup>c</sup> as first-line therapy.<sup>d</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/#:~:text=National%20Comprehensive%20Cancer%20Network%C2%AE%20%28NCCN%C2%AE%29%3A,as%20first%2Dline)

> “NCCN: Sacituzumab govitecan-hziy (TRODELVY) in combination with pembrolizumab is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC who are PD-L1 CPS ≥10,<sup>b</sup> regardless of germline BRCA1/2 PV status,<sup>c</sup> as first-line therapy.<sup>d</sup>”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/#:~:text=NCCN%3A%20Sacituzumab%20govitecan%2Dhziy%20%28TRODELVY%29%20in,as%20first%2Dline)

> “National Comprehensive Cancer Network® (NCCN®): Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or mTNBC as second-line therapy. It may be considered for later line if not used as second-line therapy.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/efficacy-data-in-mtnbc/later-line-data#:~:text=National%20Comprehensive%20Cancer%20Network%C2%AE%20%28NCCN%C2%AE%29%3A,not%20used%20as%20second%2Dline%20therapy.)

> “The NCCN recommendations differ from the sacituzumab govitecan-hziy (TRODELVY) Prescribing Information.”

Source: [TRODELVY: TRODELVY (sacituzumab govitecan-hziy) - For Healthcare Professionals, captured 2026-11-08](https://www.trodelvyhcp.com/#:~:text=The%20NCCN%20recommendations%20differ%20from%20the%20sacituzumab%20govitecan%2Dhziy%20%28TRODELVY%29%20Prescribing%20Information.)

## Related pages
- [Medical information: Trodelvy (sacituzumab govitecan-hziy): Metastatic triple-negative breast cancer](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trodelvy--metastatic-triple-negative-breast-cancer/access-and-coverage)
